Antidepressant + Placebo
DrugAntidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
NCT Number: NCT00095758
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Local Institution, Beverly Hills, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Other names: Abilify
Time frame: Baseline, Week 8
Time frame: Baseline, Week 8
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02727972
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsNCT04448327
Depressive Disorder, Depressive Disorder, Major
Charlestown, Massachusetts, United States
View Trial DetailsNCT04502758
Behavior, Behavioral Symptoms
Rochester, Minnesota, United States
View Trial DetailsNCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial Details